F. Tas Et Al. , "Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy," CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.73, no.6, pp.1163-1171, 2014
Tas, F. Et Al. 2014. Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy. CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.73, no.6 , 1163-1171.
Tas, F., Karabulut, S., Ciftci, R., Sen, F., Sakar, B., Disci, R., ... Duranyildiz, D.(2014). Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy. CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.73, no.6, 1163-1171.
Tas, Faruk Et Al. "Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy," CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.73, no.6, 1163-1171, 2014
Tas, Faruk Et Al. "Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy." CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.73, no.6, pp.1163-1171, 2014
Tas, F. Et Al. (2014) . "Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy." CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.73, no.6, pp.1163-1171.
@article{article, author={Faruk TAŞ Et Al. }, title={Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy}, journal={CANCER CHEMOTHERAPY AND PHARMACOLOGY}, year=2014, pages={1163-1171} }